Cosponsor
No direct connectionCosponsorship · Reviewed automated analysis
Compared with: Support for Medicare for All and increased access to mental health care.
The stated priority is support for Medicare for All and increased access to mental health care. The cosponsored bill is an ALS-focused research and drug-development reauthorization that supports investigational therapies for ALS and other neurodegenerative diseases, with FDA/NIH reporting and planning provisions. It does not establish Medicare for All, expand health insurance coverage generally, or specifically target mental health care access, so there is no direct substantive connection to the quoted policy goal.
“He is proud to support Medicare for All and is a champion for increased access to mental health care.”
Official statement · Captured 2026-10-28
Supporting provisions
“Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.”
“The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.”
“Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases.”
Summary-based analysis · Action predates captured statement · Narrower scope
Assessed 2026-10-28 · Review: User-authorized automated publication. Published at the user request after the bounded production backfill. Automated evidence validation passed; comparisons have not been individually audited.
Partly supportsCosponsorship · Reviewed automated analysis
Compared with: Addressing systemic disparities that affect health care access.
The cosponsored bill would advance access to treatments for ALS and other rare neurodegenerative diseases, including FDA planning to foster development of safe and effective drugs and facilitate access to investigational drugs. That supports broader access to care and therapies, but it is disease-specific and focused on research/therapeutics rather than directly addressing systemic disparities across health care access generally, so the alignment is meaningful but narrower than the stated priority.
“In the Senate, Alex has prioritized addressing the systemic disparities that affect health care access.”
Official statement · Captured 2026-10-28
Supporting provisions
“Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.”
“The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.”
“Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases.”
Summary-based analysis · Action predates captured statement · Narrower scope
Assessed 2026-10-28 · Review: User-authorized automated publication. Published at the user request after the bounded production backfill. Automated evidence validation passed; comparisons have not been individually audited.
Partly supportsCosponsorship · Reviewed automated analysis
Compared with: Guaranteeing quality, affordable, and equitable health care for every American.
The cosponsored bill meaningfully supports access to therapies for ALS by reauthorizing NIH and FDA research grants, requiring safety and efficacy review, and directing the FDA to plan actions to foster development of safe and effective drugs and facilitate access to investigational drugs. This advances affordable/accessible care in a narrow disease-specific way, but it is limited to ALS and other rare neurodegenerative diseases rather than guaranteeing quality, affordable, and equitable health care for every American.
“Alex is working to guarantee quality, affordable, and equitable health care for every American.”
Official statement · Captured 2026-10-28
Supporting provisions
“The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.”
“Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs.”
“Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases.”
Summary-based analysis · Action predates captured statement · Narrower scope
Assessed 2026-10-28 · Review: User-authorized automated publication. Published at the user request after the bounded production backfill. Automated evidence validation passed; comparisons have not been individually audited.
“The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.”Official summary source